[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563768":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":37,"collaborators":7,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Henan Institute of Cardiovascular Epidemiology","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Muwei Li, Ph.D","Fuwai central China cardiovascular hospotial","STUDY_CHAIR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Quan Guo, MD","CONTACT","+8615670510031","xinyiguoquan@163.com",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Fuwai Central China Cardiovascular Hospital","RECRUITING","Zhengzhou","450003","China","CN",{"type":28,"coordinates":29},"Point",[30,31],113.64861,34.75778,{"lat":31,"lon":30},[34],{"name":35,"role":16,"phone":36,"phoneExt":7,"email":18},"Quan Guo","15670510031",{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100563768","a-retrospective-study-on-the-factors-of-drug-coated-balloon-restenosis-100563768",false,"NCT06620458","A Retrospective Study on the Factors of Drug-coated Balloon Restenosis","RE-DCB","Inclusion Criteria:\n\n* Age:\n\n  18 years and older.\n* Diagnosis:\n\nDiagnosed with coronary artery disease with native large vessel lesions confirmed by coronary angiography.\n\n* Treatment Plan:\n\nScheduled to receive paclitaxel drug-coated balloon angioplasty.\n\n* Informed Consent:\n\nPatients have been fully informed about the nature and purpose of the study, and have voluntarily agreed to participate, with signed informed consent.\n\n* Physiological Status:\n\nCardiac function classified as NYHA I-III.\n\nExclusion Criteria:\n\n* Allergy History:\n\nKnown allergies to paclitaxel or any materials used in angioplasty (e.g., contrast agents).\n\n* Severe Complications:\n\nUncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg).\n\n* Other Medical Conditions:\n\nActive bleeding or clotting disorders.\n\n* Other serious diseases with a life expectancy of less than 1 year (e.g., advanced cancer).\n* Pregnancy or Nursing: Women who are currently pregnant or breastfeeding.\n* Participation in Other Studies: Currently participating in other clinical trials that might affect the results of this study.\n* Psychological or Behavioral Factors: History of psychiatric or behavioral disorders that could interfere with adherence to study protocols, or communication barriers that prevent understanding of study requirements.","ALL","18 Years",{"count":49,"type":50},5000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to analyze potential factors post paclitaxel drug-coated balloon angioplasty in patients with Denovo large vessels disease. It includes imaging endpoints and clinical event endpoints. Over 5000 patients are expected to be enrolled.",[54],"Coronary Artery Disease",[56],"DCB CHD IVUS OCT","2024-11-12",{"date":59,"type":60},"2024-11-14","ACTUAL",{"date":62,"type":60},"2024-10-01",{"date":64,"type":50},"2026-12-01",{"name":5,"class":6},1]